Long-term survival in stage III and IV ovarian cancer
| Autor: | E. Petru, B.U. Sevin, Susan G. Hilsenbeck, Ossi R. Koechli, Hervy E. Averette |
|---|---|
| Rok vydání: | 1991 |
| Předmět: |
Adult
Oncology medicine.medical_specialty medicine.medical_treatment Disease Postoperative Complications Internal medicine medicine Humans Stage (cooking) Radical surgery Aged Neoplasm Staging Retrospective Studies Aged 80 and over Ovarian Neoplasms Chemotherapy business.industry Obstetrics and Gynecology Combination chemotherapy General Medicine Bowel resection Middle Aged medicine.disease Combined Modality Therapy Survival Rate Lymphatic Metastasis Florida Female Lymph Ovarian cancer business Follow-Up Studies |
| Zdroj: | Archives of Gynecology and Obstetrics. 249:87-93 |
| ISSN: | 1432-0711 0932-0067 |
| Popis: | A total of 104 unselected, previously untreated patients with invasive stage III or IV ovarian cancer were operated on between 1977 and 1984. Nine patients were lost in follow-up, three died from non-malignant disease. Thirteen of the 92 eligible patients (15%) were observed to survive 5 years or longer. In the 13 long-term survivors, 4 had stage IV disease, 7 positive peritoneal cytology, 3 bowel resection, and 12 residual disease less than 2 cm after primary surgery. Retroperitoneal lymph nodes were involved in 6/9 cases. The majority of 5-year survivors (69%) received cis-platin-containing combination chemotherapy. 5/7 long-term survivors had positive second-look. At 5 years, life-quality in 9/13 patients who were free of disease, was high. It can be concluded that only patients with optimally resected stage III or IV ovarian cancer have a realistic chance of long-term survival. It is expected that increasing radicality n surgery for ovarian cancer together with platinum-based chemotherapy regimens may improve long-term survival in the future. In addition, further studies of new chemotherapeutic approaches are needed. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink